Siga Technologies (NASDAQ:SIGA) Posts Earnings Results

Siga Technologies (NASDAQ:SIGA) announced its earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $1.32 million during the quarter. Siga Technologies had a net margin of 1.31% and a return on equity of 0.40%.

Here are the key takeaways from Siga Technologies’ conference call:

• U.S. procurement timing remains uncertain. SIGA said the process for a new government contract is moving more slowly than in the past, although management continues to believe an award will be made.
• SIGA signed a Canadian TPOXX contract worth up to approximately $15 million. It includes about $9 million in firm commitments over three years, with deliveries expected to begin in 2027, and up to $6 million in options.
• The PEP program’s supplemental NDA filing is now expected in 2028. FDA-requested validation and laboratory work will take additional time, delaying the filing despite SIGA’s continued view that the program is important.
• SIGA reported approximately $42 million in product revenue for the first nine months of 2026, but had no product sales in the third quarter; quarterly net loss was approximately $3 million.
• The company ended the quarter with approximately $116 million in cash and no debt, providing financial capacity amid uncertain government procurement timing.

Siga Technologies Stock Performance

Siga Technologies stock traded up $0.04 during midday trading on Wednesday, hitting $3.17. 80,778 shares of the company’s stock were exchanged, compared to its average volume of 601,486. The stock has a market cap of $227.48 million, a price-to-earnings ratio of -63.58 and a beta of 1.10. Siga Technologies has a 12-month low of $2.83 and a 12-month high of $7.11. The firm’s 50 day simple moving average is $3.19 and its 200 day simple moving average is $4.28.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Siga Technologies in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Siga Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in SIGA. BlackRock Inc. purchased a new position in shares of Siga Technologies during the second quarter worth about $15,238,000. Dimensional Fund Advisors LP raised its stake in Siga Technologies by 6.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,702,724 shares of the company’s stock valued at $14,459,000 after acquiring an additional 165,930 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Siga Technologies by 48.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,525,960 shares of the company’s stock valued at $8,164,000 after acquiring an additional 500,880 shares during the last quarter. First Wilshire Securities Management Inc. lifted its position in Siga Technologies by 30.2% during the 1st quarter. First Wilshire Securities Management Inc. now owns 890,498 shares of the company’s stock worth $4,764,000 after acquiring an additional 206,445 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Siga Technologies by 25.6% during the 1st quarter. Renaissance Technologies LLC now owns 475,013 shares of the company’s stock worth $2,541,000 after acquiring an additional 96,913 shares during the period. 55.40% of the stock is owned by hedge funds and other institutional investors.

About Siga Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on developing and supplying medical countermeasures for high-consequence infectious diseases. Its primary product is TPOXX (tecovirimat), an antiviral medicine developed to treat smallpox. TPOXX targets orthopoxviruses, the virus family that includes variola virus, which causes smallpox, as well as mpox and other related infections. TPOXX has been approved by the U.S. Food and Drug Administration in oral and intravenous formulations for the treatment of smallpox.